Compounded Semaglutide vs. Ozempic: Are They the Same Thing?

*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting any new medication or treatment program.*

---

If you have been researching compounded semaglutide vs Ozempic, you have likely come across both "Ozempic" and "compounded semaglutide." The two terms come up together so often that many people assume they are interchangeable. They are not, and understanding the difference matters before you make any medical or financial decision.

This guide explains what each one is, how they compare, and what questions to ask when evaluating your options.

---

What Is Ozempic?

Ozempic is a brand-name injectable medication manufactured by Novo Nordisk. Its active ingredient is semaglutide, a GLP-1 receptor agonist. The FDA approved Ozempic specifically for improving blood sugar control in adults with type 2 diabetes. A separate semaglutide product, Wegovy, was approved by the FDA for chronic weight management in adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related health condition.

Ozempic is available in prefilled injection pens in doses of 0.5 mg, 1 mg, and 2 mg. The medication is manufactured to strict FDA standards at licensed pharmaceutical facilities, and every batch is subject to FDA oversight for consistency, potency, and sterility.

A landmark clinical trial, the STEP 1 study published in the *New England Journal of Medicine*, found that adults with obesity who used semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group [1]. This trial used the specific branded formulation at the doses approved for weight management.

---

What Is Compounded Semaglutide?

Compounded semaglutide is a prescription medication prepared by a licensed compounding pharmacy using semaglutide as the active pharmaceutical ingredient. It is not manufactured by Novo Nordisk and is not the same product as Ozempic or Wegovy.

Compounding is the process of preparing a medication tailored to a specific patient's needs when commercially available products do not meet those needs. Licensed compounding pharmacies operate under federal and state pharmacy law, including oversight from state pharmacy boards and, for 503B outsourcing facilities, the FDA.

Compounded semaglutide is not FDA-approved. This is not a marketing disclaimer buried in fine print. It is a meaningful regulatory fact: the FDA has not reviewed the specific compounded product for safety, efficacy, or quality in the same way it reviewed Ozempic and Wegovy. Patients who choose compounded semaglutide are choosing a legally prepared pharmaceutical product that exists in a different regulatory category.

---

*Compounded semaglutide is prepared by licensed compounding pharmacies under state and federal pharmacy law.*

---

What They Have in Common

Both Ozempic and compounded semaglutide use semaglutide as the active ingredient. Semaglutide is a GLP-1 receptor agonist, a class of medications that work by mimicking a hormone called glucagon-like peptide-1. This hormone is released naturally after eating and plays a role in regulating blood sugar, slowing gastric emptying, and signaling to the brain that you feel full.

Both require a prescription from a licensed healthcare provider. Neither is available over the counter. Both are typically administered as subcutaneous (under-the-skin) injections.

For patients who receive either medication under proper medical supervision, the mechanism of action is the same at the molecular level: semaglutide binds to GLP-1 receptors and activates them. The clinical response, including appetite reduction and slower gastric emptying, follows the same biological pathway.

That said, similar mechanism does not mean identical product. The differences below are the ones that actually matter for your decision.

---

The Important Differences

1. FDA Approval Status

Ozempic is FDA-approved. That means Novo Nordisk submitted extensive clinical trial data to the FDA, the agency reviewed it for safety and efficacy, and the agency approved the specific doses, formulations, and indications.

Compounded semaglutide is not FDA-approved. Compounding pharmacies do not submit individual formulations to the FDA for approval review. The regulatory framework that governs compounding is different from the drug approval pathway, and the FDA does not verify the safety, efficacy, or quality of compounded medications in the same way.

This distinction does not mean compounded semaglutide is inherently unsafe. It means the burden of quality assurance falls on the compounding pharmacy and the provider network, rather than on an FDA-approval process. That is why pharmacy selection and prescriber oversight matter significantly.

2. Manufacturing Source and Quality Controls

Brand-name semaglutide is manufactured by Novo Nordisk at licensed pharmaceutical facilities using validated processes. Every batch undergoes testing for potency, purity, sterility, and stability before it reaches patients.

Compounded semaglutide is prepared at compounding pharmacies, which operate under state pharmacy board oversight (503A pharmacies) or FDA inspection (503B outsourcing facilities). Quality standards vary between compounders. Some 503B facilities follow Good Manufacturing Practices similar to pharmaceutical manufacturers. 503A pharmacies follow USP sterile compounding standards, which are rigorous but different from manufacturing-level controls.

Patients should ask their provider which pharmacy fills their prescription and what accreditation or inspection history that pharmacy has.

3. Available Dosing Formulations

Ozempic is available in fixed dose pens (0.5 mg, 1 mg, 2 mg). Wegovy, approved for weight management, has a specific dose-escalation protocol beginning at 0.25 mg weekly.

Compounded semaglutide can be prepared in a wider range of doses and may be available in different formulations, including oral troches or different concentrations. This flexibility is one reason some providers prefer compounding: the ability to adjust doses more granularly for individual patients. However, formulations not found in the branded products have not been evaluated in the large clinical trials that established semaglutide's safety profile.

4. Cost

Ozempic lists at over $900 per month without insurance. Many patients with commercial insurance or Medicare have partial coverage, but prior authorization requirements and formulary restrictions can make access inconsistent.

Compounded semaglutide programs are often significantly more affordable because they are not subject to brand-name drug pricing. Prescriva, for example, offers compounded semaglutide programs starting at $159 per month, which includes a provider consultation, medication, and shipping.

This cost difference is the primary reason many patients who qualify medically seek compounded options. Research on GLP-1 access has consistently identified out-of-pocket costs and insurance coverage gaps as significant barriers to treatment, including a 2020 *JAMA Network Open* analysis of Medicare Part D coverage that documented substantial patient cost-sharing for GLP-1 medications [2].

5. Equivalence: What You Cannot Claim

It is worth being direct about this: compounded semaglutide is not the same as Ozempic or Wegovy. The FDA has issued warning letters to telehealth companies that claim or imply equivalence between compounded and branded semaglutide products. Calling compounded semaglutide a "generic" or saying it is "the same as Ozempic" is inaccurate and, under current FDA guidance, potentially unlawful.

Prescriva does not make equivalence claims. If you encounter a provider that does, treat it as a red flag about their compliance practices.

---

FDA Regulations on Compounded GLP-1s: The Current Landscape

The regulatory environment for compounded semaglutide has shifted substantially since 2024. In February 2025, the FDA removed semaglutide from its list of drugs in shortage. For 503B outsourcing facilities, this meant that one of the primary regulatory pathways for producing bulk compounded semaglutide was no longer available. Many outsourcing facilities have continued operations under state pharmacy law and under the 503B "office use" allowances, but the legal landscape is actively evolving.

What this means for patients: if you are considering compounded semaglutide, your provider should be working with a pharmacy that is operating in full compliance with current federal and state requirements. Providers and pharmacies operating under outdated shortage justifications may be in a regulatory gray area.

Ask your provider: which regulatory basis does your pharmacy rely on for compounding semaglutide, and how are they staying current with FDA guidance?

---

Why Patients Choose Compounded Semaglutide

Despite the regulatory differences, demand for compounded semaglutide has remained high. There are several reasons patients pursue compounded options through licensed telehealth providers.

Cost. The price gap between branded and compounded semaglutide is large. For patients without adequate insurance coverage, a $900/month branded drug versus a $159/month compounded program is not a trivial distinction.

Access. Insurance coverage for GLP-1 medications for weight management is inconsistent. Many commercial plans do not cover Wegovy at all. Employer-sponsored plans have been restricting GLP-1 coverage due to high costs. Compounded programs allow patients to access treatment without navigating insurance hurdles.

Availability. During the 2024-2025 semaglutide shortage period, many patients who had prescriptions for branded products could not fill them. Compounding pharmacies were able to continue supplying medication during periods when brand-name products were backordered.

Dose customization. Some providers prefer the flexibility of compounding to titrate patients more gradually or to adjust formulations for patients with specific tolerability issues.

None of these reasons changes the regulatory facts described above. But they explain why a well-informed patient, working with a reputable licensed provider and pharmacy, might rationally choose a compounded product.

---

What to Look for in a Compounding Pharmacy

If you pursue compounded semaglutide, the quality of the pharmacy your provider works with is the most important variable under your control.

503B outsourcing facility. These facilities are registered with the FDA, subject to FDA inspections, and required to follow current Good Manufacturing Practices. This is the higher regulatory standard for compounding.

PCAB accreditation. The Pharmacy Compounding Accreditation Board provides voluntary accreditation to pharmacies that meet rigorous quality standards. PCAB-accredited pharmacies have undergone independent third-party evaluation.

Certificate of Analysis (CoA). A reputable compounding pharmacy should be able to provide documentation that individual batches of medication have been tested for potency, sterility, and absence of contaminants.

State license in good standing. Your provider's pharmacy should hold an active license in your state and should have no history of significant regulatory actions.

---

How Prescriva Approaches This

Prescriva connects patients with independently licensed healthcare providers who evaluate whether compounded weight management medications are appropriate on an individual basis. All medications are prescribed by providers after a thorough medical evaluation and are filled by licensed compounding pharmacies.

Prescriva does not claim that its compounded products are equivalent to Ozempic, Wegovy, or any other FDA-approved product. Compounded semaglutide is not FDA-approved. It is a legally prepared medication option that requires a prescription, medical oversight, and an informed patient who understands the regulatory distinctions.

If you are ready to understand your options with complete transparency, the assessment process starts with a short eligibility check.

[Check your eligibility with Prescriva](/quiz)

---

Frequently Asked Questions

Is compounded semaglutide the same drug as Ozempic? No. Both use semaglutide as the active ingredient, but compounded semaglutide is a different product. It is prepared by a licensed compounding pharmacy, not manufactured by Novo Nordisk, and it is not FDA-approved. The two should not be treated as interchangeable.

Is compounded semaglutide legal? Yes. Compounded semaglutide is legal when prepared by a licensed compounding pharmacy operating under applicable federal and state law and prescribed by a licensed healthcare provider. The regulatory requirements for compounding have tightened since the FDA resolved the semaglutide shortage in early 2025, so pharmacy compliance is worth verifying.

Can I switch from Ozempic to compounded semaglutide? Potentially, but only under the guidance of your prescribing provider. Any medication change requires a provider review of your current dose, your medical history, and the specific formulation you would be switching to. Do not change medications without consulting your provider.

Does compounded semaglutide have the same side effects as Ozempic? Semaglutide's known side effects, including nausea, vomiting, diarrhea, and constipation, are related to the GLP-1 mechanism of action. Compounded semaglutide is also a GLP-1 receptor agonist, so a similar side effect profile is expected. Your provider should review side effects with you before starting treatment.

Why is compounded semaglutide so much cheaper? Brand-name pricing reflects research and development costs, manufacturing overhead, and market dynamics specific to branded pharmaceuticals. Compounding pharmacies work with the active pharmaceutical ingredient and have different cost structures. The lower price does not mean lower quality by default, but it does underscore why pharmacy accreditation and regulatory compliance matter.

Will insurance cover compounded semaglutide? Most commercial insurance plans do not cover compounded medications, including compounded semaglutide. Plans that do cover GLP-1s typically cover FDA-approved branded products specifically. Pricing through Prescriva is designed to be accessible without insurance coverage.

---

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." *New England Journal of Medicine*. 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/). DOI: 10.1056/NEJMoa2032183

1. Luo J, Feldman R, Rothenberger SD, Hernandez I, Gellad WF. "Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program." *JAMA Network Open*. 2020;3(10):e2020969. [View article](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2771731)

1. U.S. Food and Drug Administration. "[Compounding and the FDA: Questions and Answers](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)." FDA.gov. Accessed April 2026.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded semaglutide is not an FDA-approved medication. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Prescriva is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.